9 Meters Biopharma (NMTR) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free NMTR Stock Alerts Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEnergy firms likely to miss smart meter deadline, warns Which?bbc.com - December 14 at 3:12 PMDeal reached to sell some assets of bankrupt Raleigh firmbizjournals.com - November 8 at 7:34 PM9 Meters Biopharma, Inc. (NMTRQ)finance.yahoo.com - November 7 at 7:35 PM9 Meters Biopharma Inc (NMTRQ)investing.com - October 17 at 12:10 PM9 Meters Biopharma (OTC: NMTR.Q)fool.com - August 16 at 5:48 PMRaleigh firm joins worrying trend of bankruptcies for drugmakersbizjournals.com - July 18 at 8:47 PMDrug developer 9 Meters Biopharma files for bankruptcy protectionreuters.com - July 18 at 3:42 PMWhy Are 9 Meters Biopharma Shares Nosediving Today?finance.yahoo.com - July 18 at 3:42 PMTemperato resigns as CEO of Raleigh drugmakerbizjournals.com - May 30 at 11:34 PM9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndromefinance.yahoo.com - May 30 at 1:33 PM9 Meters Biopharma (NASDAQ: NMTR)fool.com - May 28 at 12:31 AMNMTR - 9 Meters Biopharma, Inc.uk.finance.yahoo.com - May 25 at 11:56 PMCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral Recommendationmsn.com - May 19 at 8:44 AM9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023finance.yahoo.com - May 15 at 7:40 PM9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesityfinance.yahoo.com - April 5 at 8:59 AMWhy this Raleigh pharma just cut half its workforcebizjournals.com - March 30 at 8:33 AM9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022finance.yahoo.com - March 28 at 10:42 AMNMTR 9 Meters Biopharma, Inc.seekingalpha.com - March 25 at 11:55 PM9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and Forecastbenzinga.com - March 22 at 12:34 AMRaleigh pharma raises $5M as phase 3 study beginsbizjournals.com - March 16 at 9:51 AM9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - March 15 at 6:38 PM9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rulesfinance.yahoo.com - March 14 at 9:25 AM9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conferencefinance.yahoo.com - March 7 at 7:36 PMSuppliers told to remove prepayment meters that were wrongly force-fittedtheguardian.com - February 23 at 11:57 PM9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conferencefinance.yahoo.com - January 31 at 12:55 PMLabour calls for halt to ‘shameful’ forced installation of prepayment meterstheguardian.com - January 17 at 5:46 PMMPs warn over forced prepayment meters as cold weather returnstheguardian.com - January 15 at 12:57 AMEnergy bills: 'I was forced onto a prepayment meter'news.yahoo.com - January 14 at 12:48 AMMillions of families forced to have prepayment gas and electric metersthetimes.co.uk - January 14 at 12:48 AM9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndromefinance.yahoo.com - November 29 at 1:28 PM9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussyfinance.yahoo.com - November 14 at 9:12 AM9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022finance.yahoo.com - November 8 at 10:36 AM9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meetingfinance.yahoo.com - October 24 at 10:54 AM9 Meters Biopharma triggers reverse stock split to maintain Nasdaq listingbizjournals.com - October 18 at 8:37 AM9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meetingfinance.yahoo.com - October 18 at 8:37 AM9 Meters Biopharma Announces 1-for-20 Reverse Stock Splitfinance.yahoo.com - October 17 at 9:18 AM9 Meters Biopharma gains after mid-stage data for short bowel syndrome drugseekingalpha.com - September 27 at 8:32 AM9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndromefinance.yahoo.com - September 26 at 5:31 PM9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 10:15 AM9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congressfinance.yahoo.com - September 1 at 8:27 AM9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conferencefinance.yahoo.com - August 31 at 10:16 AM9 Meters Biopharma, Inc. (NMTR)uk.finance.yahoo.com - August 13 at 7:29 PM9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022finance.yahoo.com - July 6 at 9:44 AMRaleigh drugmaker shifts focus after trial setbackbizjournals.com - July 5 at 7:51 AM9 Meters stock falls despite drug showing promise in short bowel syndrome trialseekingalpha.com - June 30 at 11:56 AM9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drugseekingalpha.com - June 30 at 11:56 AM9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndromefinance.yahoo.com - June 30 at 11:56 AM9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndromefinance.yahoo.com - June 30 at 11:56 AMRaleigh pharma sees stock tumble after stopping trial. Now what?finance.yahoo.com - June 22 at 7:14 AM9 Meters stock slumps 54% as phase 3 Celiac disease trial of larazotide gets axedseekingalpha.com - June 21 at 4:14 PM Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. NMTR Media Mentions By Week NMTR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMTR News Sentiment▼0.000.41▲Average Medical News Sentiment NMTR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMTR Articles This Week▼00▲NMTR Articles Average Week Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EIGR News REVB News VRAX News BDRX News SPRC News BBLG News BXRX News NEPT News TCBP News AKAN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMTR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
